Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative medications function by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to consumption. By activating GLP-1 receptors in the pancreas, these agents boost insulin secretion and suppress

The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing variations in their